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 Mycobacterium tuberculosis is the leading cause of death by an infectious disease and 
remains one of the top overall causes of mortality worldwide. With antibiotic resistance rising 
and persistence an impending threat, research into mechanisms of antibiotic tolerance is 
pertinent. The stringent response is responsible for decreased replication and a reduced 
metabolic state in stressed conditions, a physiological state that is thought to be a major 
contributor to latent tuberculosis infection and the lengthy duration of treatment for 
tuberculosis. The RelMtb enzyme regulates accumulation of the stringent response effector 
molecule, (p)ppGpp. It is hypothesized that learning to control this enzyme may allow 
modulation of the M. tuberculosis stringent response, potentially leading to a better 
understanding of antibiotic tolerance and immune evasion, as well as new methods of treating 
tuberculosis. To learn more about this pathway and deduce whether or not accumulation of 
(p)ppGpp is sufficient to induce the stringent response. We have generated a conditional RelMtb 
overexpression strain by molecular cloning techniques that lacks the ability to hydrolyze 
(p)ppGpp. This strain responds to an anhydrotetracycline inducing agent by increasing 
expression of the gene of interest. Inducible expression at the genetic and protein level has 
been confirmed, but more time and data are needed to characterize this strain and determine 
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Phthisis (φθίσης), meaning “wasting”, and “consumption” were commonly used to 
describe pulmonary tuberculosis (TB) for many years. Johann Schoenlein, however, is credited 
with formally establishing the current name of the disease in 1839, based on the tuber, or 
potato-like structure, found on gross examination of diseased organs (Figure 1). While TB likely 
affected humans before, it is first described in detailed records in ancient Greece, with 
references in the Hippocratic Collection [1]. Widespread for numerous years and consistently in 
the top three causes of death in the United States until the 1920’s [2], TB has claimed the lives 
of many world-renowned historical figures, including Frédéric Chopin, John Keats, and the 
Brontë sisters (Charlotte, Emily, and Anne) [3]. Among the scientists and physicians who 
succumbed to TB because of their dedication to its study are French physicians Gaspard Bayle 
and René Laennec, whose discovery of the stethoscope endures as a trademark tool of medical 
doctors today. TB remained one of the top ten causes of death worldwide in 2016 [4], with 1.7 
million people dying of the disease and almost one third of these deaths occurring in people 
affected by HIV/TB coinfection [4]. In addition, the greatest incidence of TB cases annually is in 
sub-Saharan Africa and southeast Asia. With antibiotic resistance, multi-drug resistant TB (MDR-
TB), and extremely drug resistant TB (XDR-TB) on the rise, one in five people receiving the MDR-
TB treatment they need, and the issues of latent TB infection and persistence looming, much 
work is to be done if the World Health Organization (WHO) goal of eliminating TB by 2030 is to 
be achieved [4,5]. 
 Past treatments for TB include everything from fasting and exorcisms to horseback 
riding and the practices of bleeding and purging popular into the 19th century. In 1859, German 
physician Hermann Brehmer formally introduced the idea of the sanatorium, a retreat for 
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tuberculous patients, where exposure to fresh air, rest, and a nutritious diet, along with 
supervised medical care, was said to allow the lungs to recover. Patient populations in sanitoria 
rose from just under 12,000 in 1908 to more than 90,000 in 1942, providing an ideal 
environment for introduction of collapse therapy. In its most basic form, collapse therapy was 
contraction of the lung into an uninflated state by various mechanisms to allow it to heal, with 
incorporation of a number of refinements over time before the advent of chemotherapy. 
Among the first antibiotics developed to treat TB were para-amino salicylate, streptomycin, and 
Figure 1 Gross pathology of tuberculosis Posterior view of New Zealand white rabbit lungs affected by tuberculosis. 
At 5 weeks post infection numerous tubercles or tubers, swollen, potato-like structures, can be seen, and were the 
basis for Johann Schoenlein’s naming of the disease [72]. 
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isonicotinic acid hydrazide, the latter of which remains a critical component of current anti-TB 
therapy as the derivative isoniazid [1]. With the emergence of HIV in the 1980’s and the WHO’s 
declaration of TB resurgence as a global health emergency in 1993, focus on a new strategy was 
needed. The current first-line treatment regimen for antibiotic sensitive TB employs 
combination therapy utilizing rifampin, isoniazid, ethambutol, and pyrazinamide for six to nine 
months. In addition, introduction of directly observed therapy, short course (DOTS) has helped 
ensure patients complete the course of treatment, and aids in preventing antibiotic resistance 
[6]. However, treatment of MDR-TB requires at least 18 months of treatment with antibiotics 
that are less effective, more costly, and more toxic. With the emergence of XDR-TB, treatment 
options have become even more limited. Patients and physicians are forced to combat XDR-TB 
using an ever shrinking list of antibiotics with a concomitantly growing list of side effects, leaving 
a narrow therapeutic margin between eradicating the infection and harming the patient [7]. 
 Numerous philosophers and scientist have made predictions through the years about 
the type of disease TB is, and what might be the cause of such a devastating disease. Though he 
had no rigorously validated evidence, Aristotle postulated that TB is spread from person to 
person by a disease producing agent in the air breathed by people affected with the disease. 
The Greek physician Aretaeus also noted and described in great detail the various clinical 
manifestations of chronic TB [1]. Franciscus de la Boe, better known as Sylvius, observed 
nodules in the organs of TB patients upon autopsy and asserted that these tubercles, or 
swellings, are the precursor to cavities. Because of this finding, he and his peers were able to 
differentiate TB from other wasting diseases. Pierre Desult later suggested these tubercle 
structures develop as a direct result of TB, a hypothesis confirmed by William Stark and 
Matthew Baillie in the course of conducting autopsies that showed tubercles arise and progress 
to cavities in response to TB disease [1]. Also known for his work with post-mortem TB cases, 
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Gaspard Bayle chronicled detailed patient histories, allowing immense leaps forward in piecing 
together clinicopathological correlations [1]. Confirming some theories about the cause of TB 
and quashing others, Robert Koch’s discovery of the etiological agent of TB in 1882 proved a 
momentous event in history [8]. Not only was Koch able to culture and view the tubercle 
bacillus, he proved a causal relationship between the bacillus, named Mycobacterium 
tuberculosis, and TB disease, developing his famed Koch’s Postulates in the process. He also 
experimentally validated the idea that transmission occurs from one human to another via 
cavitation in the lungs based on visualization of the tubercle bacillus in sputum from human TB 
patients [1,8]. 
 
Mycobacterium tuberculosis infection 
The causative agent of tuberculosis (TB), Mycobacterium tuberculosis, is a Gram 
positive, acid-fast, rod-like organism [9] that primarily infects human lung tissue, but is able to 
disseminate to other organs [10]. M. tuberculosis enters the human body by inhalation of 
infectious aerosol particles and passes into the alveoli of the lungs. The classical theory of M. 
tuberculosis infection postulates that resident alveolar macrophages engulf the bacterium 
through the process of phagocytosis, confining M. tuberculosis to a phagosome within the 
macrophage. Depending on their activation state, some macrophages are able to immediately 
kill the engulfed bacteria. Others do not have the capacity to do so and become a haven for 
bacterial multiplication [11]. Two subsets of macrophages, active and naïve, participate in the 
initial response against M. tuberculosis infection. Activated macrophages follow the normal 
process of phagosome maturation, where a phagosome containing the bacterium fuses with a 
lysosome containing hydrolytic enzymes that break down various biomolecules. Thus, M. 
tuberculosis is degraded and killed in the phagolysosome before multiplying and infecting 
5 
 
additional immune cells. However, when M. tuberculosis infects naïve macrophages, the 
bacteria have evolved to circumvent the process of phagosome maturation, preventing the 
acidic pH change necessary for phagolysosomal fusion and bacterial degradation [12]. 
Consequently, the bacteria can continue to multiply within the macrophage phagosome, 
eventually causing death by apoptosis or necrosis [13], or enter into a dormant state to evade 
immune and antibiotic pressure. Regardless, all infected macrophages produce cytokines that 
recruit additional mononuclear immune cells from surrounding blood vessels to the tissue. 
These immune cells, along with proliferating bacteria, form the early structure of the traditional 
tuberculous granuloma. As granuloma formation progresses, established cells begin to exhibit a 
range of differing phenotypes, including lipid-rich foam cells, macrophages displaying epithelioid 
Figure 2 Cellular contents of the necrotic granuloma At the center of the necrotic granuloma are M. tuberculosis 
bacteria and infected, dying macrophages that, together, comprise the caseum. Additional granulomatous layers 
surrounding the necrotic center mostly consist of modified cell types, such as foam cells, epithelioid macrophages, 
and multinucleated giant cells. Other immune cells, including natural killer (NK) cells, neutrophils, and dendritic cells 
are also found throughout the granuloma. Adaptive immune cells, however, usually remain at the edges and are 
traditionally thought to be precluded from leaving the granuloma by a fibrous cuff that forms as part of the 
maturation process [13]. 
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characteristics, multinucleated giant cells, and various forms of cell death [13] (Figure 2). 
Bacterial replication decreases as the vasculature of the infected tissue recedes, new 
lymphocytic cells are recruited, and a fibrous cuff begins to form around the granuloma core. 
This fibrotic edge excludes many lymphocytes from the granulomatous structure, but is thought 
to contain and prevent spread of bacteria to other parts of the lung [14]. However, recent 
studies are beginning to challenge this paradigm by showing infected cells are capable of 
crossing the fibrotic capsule and migrating out of the granuloma [13,15-17]. Dying cells within 
the granuloma often undergo caseous necrosis that leads to cellular fragmentation and 
degradation, giving rise to the so called caseum at the center of the granuloma and its 
Figure 3 Mycobacterium tuberculosis infection M. tuberculosis enters the human body by inhalation through the 
airways and passes into the alveoli of the lungs. Here it infects macrophages, succumbing to immune mediated killing 
or evading degradation by circumventing the pH change that takes place. Cytokines produced by infected 
macrophages recruit additional immune cells, which begin to form the early structure of a granuloma. Debris left in 
the wake of dying cells within a maturing granuloma give rise to the caseum, which either hardens to form a 
permanent tubercle or softens and liquefies. These liquefied contents are expelled from the lungs upon coughing, 
leaving a hollow cavity exposed to the airways. This open access to the outside air is an ideal environment for M. 
tuberculosis replication, dissemination, and transmission to other individuals, continuing the cycle of disease [76]. 
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characteristic cottage cheese-like appearance [14]. Due to currently unknown stimuli within the 
granuloma microenvironment, the caseum either hardens or softens. Hardening of the caseum 
is associated with a lower bacterial burden, whereas a plethora of bacteria are commonly seen 
in softening caseum [13]. With a lack of bacterial control and disease progression the caseum 
liquefies and is expelled from the lungs, leaving a hole visible by chest X-ray (Figure 4) where 
there was previously healthy lung tissue. This cavitation provides a prime environment for 
extracellular bacterial replication and connects what was once the granuloma’s center to the 
Figure 4 Comparison of normal and diseased lungs Radiographic and histological comparison of human lungs in 
individuals without (A, C) and with (B, D) tuberculosis. A) Normal chest X-ray with dark regions indicating normal, air-
filled lung tissue [71]. B) Abnormal chest X-ray with white opacity in the upper right lobe (left side of X-ray) 
characteristic of lung disease. The dark circular region within the white opacity signifies an open space and correlates 
with cavitation, strongly suggesting TB disease [74]. C) Histologically normal lung tissue. H&E staining reveals blood 
vessels, a bronchiole, and normal alveoli with ample space for exchange of oxygen [75]. D) Histologically abnormal 
lung tissue with H&E staining showing the fibrotic wall (F) and necrotic center (N) of a granuloma. These formations 




airways of the lungs. Coughing due to irritation from damaged lung tissue disseminates bacteria 
into the outside air, exposing surrounding individuals to infectious aerosol particles that can be 
viable for several hours and perpetuating the cycle of disease (Figure 3) [14].  
 
Mycobacterium tuberculosis resistance, persistence, and latent TB infection 
 Antibiotic susceptible TB is treatable utilizing 6 to 9 months of therapy involving a 
combination of different antibiotics. However, disease caused by antibiotic resistant strains of 
M. tuberculosis requires a minimum of 18 months of therapy with multiple antibiotics, which are 
less effective, more costly, and more toxic than those in the standard first-line regimen [7]. 
These resistant bacteria contain genetic mutations or acquire extra genes through horizontal 
gene transfer that allow them to thrive despite antibiotic pressure typically sufficient to kill 
bacteria [18]. However, persistence and antibiotic tolerance are defined by different qualities 
than those characteristic of antibiotic resistance. The physiological state of ceased replication 
and reduced metabolism in the presence of antibiotic pressure has been identified as 
persistence, and bacteria capable of undergoing this process are often tolerant to antibiotics. 
This antibiotic tolerance is characterized by survival of prolonged exposure to antibiotics, 
despite continued susceptibility to inhibition at the minimum inhibitory concentration. 
However, these changes are non-heritable and if antibiotic pressure is removed, descendants of 
antibiotic tolerant bacteria are susceptible to killing by antibiotics [19,20]. Persistent bacteria 
are more difficult to target than actively replicating M. tuberculosis, as the majority of first-line 
treatments, such as isoniazid, interfere with cell wall metabolism or otherwise require active 
replication to be effective. Pyrazinamide and rifampin are the primary antibiotics targeting 
nonreplicating, persistent M. tuberculosis [21]. This nonreplicating population of bacteria is 
thought to contribute to the prolonged duration of TB treatment, and to comprise the 
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population of M. tuberculosis responsible for infection without clinical symptoms or 
radiographic evidence of disease, termed latent TB infection (LTBI) [21,22]. 
 An estimated one third of the world’s population is latently infected with M. 
tuberculosis [4]. Though it is difficult to provide concrete proof of the physiological and 
metabolic state of M. tuberculosis during LTBI due to the inability to isolate bacteria during this 
phase of disease, various tissues, including adipose depots [23], from individuals who died of 
causes other than TB have been found to harbor M. tuberculosis [24]. In addition, lymph node 
material from individuals negative for TB disease upon gross and histological examination 
postmortem is cultivable for M. tuberculosis, indicating humans can be infected with viable M. 
tuberculosis in the absence of clinical and pathological evidence of disease and that the 
supposed quiescent state of these bacteria is reversible [25,26]. The ability of M. tuberculosis to 
be resuscitated in the absence of immune or antibiotic pressure creates bacterial populations 
fully capable of replicating and dividing and introduces the possibility of reactivation of disease 
many years after infection [27]. This reactivation perpetuates the cycle of disease, forming a 
barrier to TB elimination. As such, a better understanding of LTBI and persistence is essential in 
accomplishing the goal of eliminating TB and protecting the world’s populations from disease. 
Because the bacterial phenotypes during LTBI and persistence may be similar, learning about 
one may serve to elucidate knowledge about the other. In this line of thinking, researchers are 
studying mechanisms of growth restriction and metabolic control. One such mechanism is the 
stringent response, a complex pathway necessary for extended survival of many bacteria, 






The stringent response 
The stringent response is one method by which both Gram-positive and Gram-negative 
bacteria [29,30], as well as plants [31], respond to varying types of stress. In these organisms, 
the stringent response is largely mediated by hyperphosphorylated guanosine, an alarmone 
signal that alerts the cell to adverse conditions. This molecule is synthesized in various bacteria 
by the key stringent response factor Rel and its homologs. The enzyme transfers two terminal 
phosphates from ATP to GTP or GDP, forming two different molecules termed 
pentaphosphorylated guanosine (pppGpp) or tetraphosphorylated guanosine (ppGpp), 
respectively, and collectively referred to as hyperphosphorylated guanosine [(p)ppGpp] [29]. 
These molecules are hydrolyzed to GTP or GDP and inorganic pyrophosphate (PPi) [32] by SpoT 
homologs, maintaining a balance of (p)ppGpp and ensuring adequate cellular homeostasis when 
conditions are optimal (Figure 5A). However, bacteria experiencing nutrient restriction 
accumulate (p)ppGpp (Figure 5B) and, when the alarmone reaches sufficient levels, the stringent 
response is triggered [33]. Resulting physiological changes lead to a slowly replicating, persistent 
phenotype characterized by disrupted RNA polymerase (RNAP) function [34] and decreased 
rRNA and tRNA synthesis, diverting resources away from unessential transcription and 
translation [29,35]. In addition, the stringent response inhibits cellular metabolism while 
simultaneously allowing redirection of resources previously utilized for this purpose to 
upregulate amino acid biosynthesis and production of universal stress proteins for stress 
defense [29]. While definitive answers about the details of (p)ppGpp targets and its mechanism 
of action remain controversial, progress has been made in gaining knowledge about and better 






Figure 5 (p)ppGpp synthesis and hydrolysis in nutrient rich and nutrient starvation conditions (p)ppGpp is 
maintained at different levels depending on nutrient availability within the cell. Shown is the reaction for GTP and 
ATP. The reaction for GDP and ATP is the same, with the exception of beginning the reaction with GDP instead of GTP. 
A) In nutrient rich conditions monofunctional E. coli RelA or bifunctional M. tuberculosis RelMtb synthesizes baseline 
amounts of (p)ppGpp by removing two terminal phosphates from ATP to GTP, leaving AMP as a byproduct. E. coli 
SpoT or M. tuberculosis RelMtb hydrolyzes (p)ppGpp at baseline levels by removing the two 3’ phosphates from 
(p)ppGpp, creating inorganic pyrophosphate (PPi) as a byproduct, to maintain homeostatic amounts of (p)ppGpp. B) 
In nutrient starvation conditions RelA or RelMtb synthesis rates and affinity for GTP, GDP, and ATP increase, whereas 
SpoT or RelMtb affinity for (p)ppGpp and hydrolysis rates decrease. The resulting accumulation of (p)ppGpp induces 
the stringent response. C) Predicted accumulation of (p)ppGpp and induction of the stringent response in nutrient 
rich conditions under experimental conditions where hydrolysis-deficient RelMtb synthesizes (p)ppGpp without the 
accompanying hydrolysis necessary to maintain homeostatic levels of this alarmone. 
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At least one ppGpp binding site exists in Escherichia coli RNAP and transcriptional 
regulation after binding of the alarmone is evidenced by reduced synthesis of genes known to 
be under stringent control [36]. The crystal structure of ppGpp bound to Thermus thermophilus 
RNAP also suggests multiple possible mechanisms for this transcriptional regulation [34]. In 
addition, DnaK suppressor A (DksA), a protein connected to the cellular stress response [37] and 
required for rRNA regulation in changing environmental conditions [38], enhances ppGpp 
stability and transcriptional inhibition when both are bound to the E. coli RNAP. As determined 
by the crystal structure of DksA and biochemical analyses, a coiled coil is present at the tip of 
the protein which is located at the catalytic center of RNAP. Upon modeling of the T. 
thermophilus RNAP-ppGpp-DksA complex based on separate crystal structures of each molecule, 
one of two ppGpp bound magnesium ions (Mg2+) at the catalytic center of the RNAP is likely 
coordinated by DksA. The bonds that form this coordination are thought to occur first, 
stabilizing ppGpp and allowing DksA to negotiate binding to the RNAP as it wraps around the 
structure with a hinge-like motion [39]. In addition to direct effects on RNAP, sigma factor 
binding is also altered in the stringent response, potentially facilitating broad transcriptional 
changes. 
Working in concert with each other, the molecules involved in the stringent response 
pathway produce a persistent, nonreplicating physiological state. This altered state facilitates 
bacterial persistence and LTBI in the face of antibiotic and immune pressure, despite the lack of 
genetic resistance to many cell wall-active antibiotics [29]. The endurance of these bacteria 
culminates in increased bacterial survival and is thought to be one of several barriers to 
reducing the duration of treatment and curing disease in patients. Prompting phenotypically 
tolerant bacteria to emerge from dormancy by modulating the stringent response may render 
persistent, antibiotic tolerant pathogens more susceptible to killing by first-line antibiotics. A 
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particular target of interest central to this concept, RelA in Escherichia coli is a well-studied 
protein that remains a major component in regulating (p)ppGpp production and activation of 
the stringent response. 
 
RelA and SpoT in Escherichia coli 
 Escherichia coli is a Gram-negative, rod shaped coliform found ubiquitously in the 
environment [9]. Both nonpathogenic and pathogenic strains of E. coli are prevalent, among 
which exist enterohemorrhagic serotypes associated with diseases such as food-borne illness 
and hemolytic uremic syndrome [40]. Despite more than fifty years of dedication to uncovering 
the intricacies involved in the stringent response, the roles of E. coli enzymes RelA and SpoT in 
this pathway remain complex and our understanding limited. Most studies of these enzymes 
occur under amino acid deprivation, but varying responses ensue under different stressors. 
Simply altering the type of nutrient withheld can eliminate or produce dramatic changes in 
numerous aspects of cellular physiology [29]. While there is still much to learn about the 
complexities of these enzymes, considerable progress has been made in elucidating their roles 
in the stringent response. 
Under nutrient restriction, specifically amino acid deprivation, RelA operates as a 
monofunctional enzyme requiring Mg2+ to perform the (p)ppGpp synthesis described above 
[41,42]. SpoT is a bifunctional enzyme also capable of synthesizing (p)ppGpp under specific 
conditions. Its predominant function, however, is manganese (Mn2+) dependent (p)ppGpp 
hydrolysis and degradation [43,44] to maintain homeostatic levels of this molecule. In addition 
to Mg2+, (p)ppGpp synthesis by RelA also requires ribosomes, cognate mRNA, and uncharged 
tRNA positioned in the receptor site of the ribosomal complex [45]. RelA binds to this ribosomal 
complex at a unique location, both the 50s and 30s subunits interacting with the end of the RelA 
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C-terminus. The positioning of RelA in this manner allows the acceptor end of the uncharged A-
site tRNA to bind and wrap around the beginning of the C-terminus, sterically hindering binding 
of charged tRNA, stalling protein synthesis, and presumably promoting (p)ppGpp synthesis by 
RelA [46]. 
 
The Mycobacterium tuberculosis enzyme RelMtb 
Unlike E. coli [29] and other organisms [25,42,47], M. tuberculosis encodes a 
bifunctional Rel/SpoT homolog (RSH) 738 amino acids in length with both phosphotransferase 
and phosphohydrolase activities. RelMtb contains a C-terminal domain (CTD) and an N-terminal 
domain (NTD) [48] (Figure 6A). The NTD, which is responsible for dual synthesis and hydrolysis 
of (p)ppGpp [32] (Figure 5A), contains overlapping subdomains with separate catalytic sites for 
each of these two functions [49] (Figure 6B). The transferase activity of both RelA and RelMtb 
depends upon the presence of Mg2+. However, while providing these metal ions in excess does 
not limit monofunctional RelA performance [42], inhibition of bifunctional RelMtb (p)ppGpp 
synthesis does occur due to a charge reversal in a conserved motif within the synthesis 
subdomain [42,49]. Additionally, the hydrolysis subdomain of RelMtb relies on Mn2+ for hydrolysis 
function and, like its synthesis counterpart, is inhibited by excess levels of Mn2+ [49]. 
Furthermore, specific amino acid residues critical for transferase and hydrolase activity have 
been identified. Mutation of either the glycine or histidine at position 241 or 344, respectively, is 
sufficient to eliminate the synthesis function of the NTD while maintaining the ability to 
hydrolyze (p)ppGpp [48]. Conversely, an amino acid doublet in a conserved region of the 
hydrolysis subdomain is predicted to be essential for coordinating cations [50] and mutation of 
either the histidine or aspartic acid at position 80 or 81, respectively, abolishes hydrolysis 
activity while at the same time leaving synthesis function intact [48] (Figure 6B). 
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While purified, full length RelMtb is capable of simultaneous maximal (p)ppGpp synthesis 
and maximal hydrolysis [49], regulation of these NTD functions occurs at several levels in the 
presence of biological regulators and is often mediated by the CTD. The RelMtb activating 
complex (RAC) is a combination of the RelMtb enzyme, ribosomes, tRNA, and cognate mRNA. 
Utilizing this RAC, RelMtb is capable of altering the rate of its synthesis and hydrolysis functions. 
When the RAC contains charged tRNA, representing abundant availability of nutrients, both the 
synthesis and hydrolysis functions remain at basal levels. However, in the presence of 
uncharged tRNA, representing amino acid depletion and mimicking starvation conditions, the 
synthetase affinity for its GTP/GDP/ATP substrates increases, as well as the rate of (p)ppGpp 
synthesis. Concurrently, the affinity of the hydrolase for its (p)ppGpp substrate and the rate at 
which it catalyzes hydrolysis is considerably reduced, leading to accumulation of (p)ppGpp and 
induction of the stringent response. In contrast, when the CTD is not present, the synthesis and 
Figure 6 Schematic of mycobacterial Rel NTD and CTD Spatial representation of known subdomains of the full length 
mycobacterial Rel protein. A) NTD (1-394) containing the hydrolase (green), synthetase (salmon), and overlapping 
hydrolase/synthetase (yellow) subdomains. CTD (395 – 738) containing the TGS (purple) and ACT (pink) subdomains 
of the full length mycobacterial Rel protein [73]. B) Hydrolysis and synthesis subdomains of mycobacterial Rel with 
the HD domain (blue). Specific amino acid residues essential for hydrolysis or synthesis function are indicated by small 
colored squares [48]. 
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hydrolysis rates remain at basal levels even in the presence of the RAC. This lack of regulation in 
the absence of the CTD is consistent regardless of whether the NTD contains the synthetase, 
hydrolase, or both subdomains [48]. The mechanism of CTD regulation has been further studied 
in Mycobacterium smegmatis, a nonpathogenic species of Mycobacteria often used to inform 
future studies in M. tuberculosis. 
M. smegmatis contains a bifunctional RSH termed RelMsm with a similar NTD comprised 
of phosphosynthetase and phosphohydrolase subdomains and a CTD containing a Threonyl 
tRNA synthetase, GTPase, and SpoT (TGS) subdomain, as well as an Aspartate kinase, Chorismite 
mutase, and TyrA (ACT) subdomain (Figure 6A). RelMsm (p)ppGpp synthesis increases in the 
presence of uncharged tRNA. However, when the CTD of RelMsm is cleaved, leaving only the NTD, 
the synthesis reaction is no longer affected by addition of uncharged tRNA [51]. Mutation of 
four cysteine residues conserved across RSH reveals mutation of the cysteine at position 692 is 
required to render full length RelMsm unresponsive to uncharged tRNA. Fluorescence resonance 
energy transfer and anisotropy measurements indicate a conformational change suggesting 
movement of the cysteine at position 692 away from the NTD into a more compact CTD 
formation when uncharged tRNA binds to RelMsm, providing more space for synthesis substrates 
to enter the catalytic site at the appropriate subdomain [52]. This finding is supported by the 
existence of a flexible, conserved linker region between the TGS and ACT subdomains [53]. In 
addition to regulation by an uncharged tRNA induced conformational change of the CTD, 
alternate ligand binding to this portion of RelMsm can cause the protein to unfold and decrease 
synthetase activity. Isothermal titration calorimetry confirms binding of (p)ppGpp to the RelMsm 
CTD at two separate regions that are potentially adjacent to each other when the protein’s 
tertiary structure is intact. Though this (p)ppGpp binding is weak, mutations at conserved 
residues within the two identified regions abolish the ability of excess (p)ppGpp to decrease 
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synthesis, leading to the idea of a negative feedback loop between RelMsm and (p)ppGpp that 
regulates (p)ppGpp accumulation within the bacteria [54]. 
In addition to regulation at the enzymatic level, components in the cell also regulate 
RelMtb transcription. Among other functions, the transcription factor Sigma factor E (SigE) aids in 
increasing transcription of RelMtb [55]. In the mprAB-sigE-rel pathway inorganic polyphosphate 
[poly(P)] chains are utilized to phosphorylate MprB, the first unit of a two-component signal 
transduction system. In the second step of this system MprB phosphorylates MprA, 
consequently inducing synthesis of SigE and increased transcription of RelMtb. Upstream of this 
signaling pathway, polyphosphate kinase (PPK) synthesizes poly(P) from ATP and inorganic 
phosphate (Pi) stores in the cell. Two hydrolytic exopolyphosphate kinases, PPX1 and PPX2, in 
turn degrade poly(P), maintaining a balance of the molecule in the cell. Increasing levels of 
poly(P) also induce the stringent response, assisting in survival during the stress conditions of 
stationary phase culture [57]. (p)ppGpp inhibition of PPX hydrolysis is postulated to allow the 
buildup of poly(P) chains in the cell, which feed into the mprAB-sigE-rel signaling pathway by 
preferentially phosphorylating MprB and consequently increasing RelMtb transcription as 
described above. 
RelMtb not only produces (p)ppGpp in cell-free systems, but also during nutrient 
starvation in its native M. tuberculosis. A RelMtb knockout strain (ΔrelMtb) does not produce 
(p)ppGpp at detectable levels and displays a survival defect in various nutrient depleted systems 
[28]. In vivo results in mice [58] and guinea pigs [59], both model organisms for persistent TB 
infection, mirror the in vitro phenotype of reduced survival. While the bacterial burden in lung 
tissue remains the same for wild type and ΔrelMtb strains in the acute phase of infection, the 
bacterial burden in lungs of animals exposed to ΔrelMtb is reduced during the chronic phase of 
infection [58,59]. In addition, gross pathology and histopathology of lung tissues are less severe 
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in ΔrelMtb-infected animals [58]. This attenuated phenotype of the ΔrelMtb strain, particularly 
during the chronic phase of infection, and association of the knockout with altered expression of 
genes important for survival under stress, establishes RelMtb as an important factor in long-term 
survival of M. tuberculosis in the host. However, much remains to be understood about this 
multifaceted regulator of the stringent response. Additional studies are necessary to investigate 
questions that persist and illuminate mechanistic details. 
 
Study outline 
The attenuated phenotype of ΔrelMtb suggests the stringent response pathway may 
represent a significant therapeutic target. Disrupting the stringent response through modulation 
of RelMtb provides the opportunity to gain a better understanding of this pathway in 
mycobacterial persistence. Therefore, a complementary approach to the currently published 
RelMtb knockout studies is proposed and creation of a strain capable of inducible RelMtb 
overexpression and (p)ppGpp accumulation has been undertaken. Specifically, this thesis details 
generation of a relMtb knock-in strain using molecular cloning techniques. Previous studies have 
shown that (p)ppGpp hydrolysis function is eliminated in a recombinant RelMtb protein 
containing a point mutation leading to an amino acid change at codon 81 in the hydrolysis 
domain, while (p)ppGpp synthetic function is not affected [48]. Site-directed mutagenesis was 
employed to create this point mutation, modifying the aspartic acid at position 81 to an alanine. 
The hydrolysis-deficient relMtb gene was cloned into a tetracycline-inducible M. tuberculosis 
plasmid containing a hygromycin resistance cassette. After confirmation of successful gene 
insertion by gel electrophoresis and Sanger sequencing, the plasmid was transformed into the 
wild type M. smegmatis laboratory strain mc2155. Upon selection of successfully transformed 
hygromycin resistant colonies, inducible expression of relMtb was confirmed at both the gene and 
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protein level by quantitative polymerase chain reaction (qPCR) and western blot, respectively. 
Consequently, this hydrolysis-deficient relMtb knock-in strain of M. smegmatis can be used to 
characterize mycobacterial phenotypes during induction of the stringent response. In addition, 
while the teton knock-in system described here is capable of answering relevant in vitro 
questions, it is also a tool that can be easily extended to future in vivo experiments due to the 
bioavailability and tolerability of the inducing agent, doxycycline.  
Utilizing a relMtb knock-in strain that permits inducible accumulation of (p)ppGpp allows 
validation of the hypothesis that induction of the stringent response is sufficient for entry into a 
growth restricted, persistent state. Understanding the role of RelMtb and learning how to 
modulate the stringent response in the laboratory introduces the possibility of targeting 
persistent bacilli using small molecule inhibitors of the RelMtb enzyme. Using this strategy, 
bacteria may be rendered susceptible to killing by cell wall-active agents targeting replicating 
organisms. This novel therapeutic approach may allow current antibiotics to work more 
efficiently and, therefore, shorten the duration of curative treatment for TB. 
 
Materials and Methods 
Culture conditions and plasmid isolation 
 All Escherichia coli cultures were grown in Luria-Bertani (LB) broth (VWR J106-500G) or 
on LB agar containing 200µg/mL hygromycin (Sigma H3274-100MG) or 100µg/mL ampicillin 
(Sigma A9518-5G) for 16 – 20 hours. Plasmids were isolated from culture using the QIAprep spin 
miniprep kit (Qiagen 27104) following the manufacturer’s protocol. M. smegmatis mc2155 
cultures were grown in Middlebrook 7H9 broth (Becton Dickinson 271310) supplemented with 
0.4% glycerol (Fisher Scientific G33-500), 10% OADC (Becton Dickinson 212351) and 0.05% 
Tween 80 (Fisher Scientific BP338-500) until log phase (0.1-0.6 OD) or on 7H10 agar (Becton 
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Dickinson 262710) supplemented with 1% glycerol and 10% OADC for four days unless stated 
otherwise. 
 
PCR amplification for molecular cloning 
 Genes of interest were amplified from specified genomic DNA sources using the 
polymerase chain reaction (PCR) with Platinum Hot Start PCR 2x Master Mix (Invitrogen 13000-
012). PCR reactions were carried out according to the manufacturer’s protocol. Briefly, 
components were mixed to achieve the following final concentrations: 1x Platinum Master Mix, 
20% Platinum GC Enhancer, 0.2μM forward and reverse primers (Table 1), ~100ng template 
DNA, and nuclease free water to 25μL. Reactions were performed on a Bio-Rad MyCycler 
thermal cycler at an initial denaturation temperature of 94°C for 2 minutes followed by thirty-
five cycles of denaturation at 94°C for 30 seconds, annealing at temperature corresponding to 
specific primers listed in Table 1 for 30s, and extension at 72°C for 1 minute/kb (2 minutes for 
relMtb and 1 minute for gfp). Reactions were then held at 4°C until used for molecular cloning. 
 
Agarose gel electrophoresis 
 All PCR and plasmid amplifications, as well as restriction digests, were confirmed by 
agarose gel electrophoresis. Briefly, the entire volume of plasmid product or a 5μL aliquot of 
gene product was mixed with 6x loading dye (NEB B7024S or Fisher Scientific R0611) to a final 
concentration of 1x loading dye. Samples were loaded into an agarose gel containing final 
concentrations of 1x Tri-acetate-EDTA (TAE), 1% agarose (BioWhittaker Molecular Applications 
5004), 0.5μg/mL ethidium bromide (Sigma E1510-10mL), and DI water to the desired final 
volume. A GeneRuler 1kb Plus DNA ladder (Fisher Scientific SM0314) was loaded as a known 
standard to compare and identify sizes of DNA products and gels were run at 80V for 45 
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minutes. Gels were imaged using a Bio-Rad Gel Doc EZ imager or, alternatively, a Spectroline 
ultra violet transilluminator when DNA excision was required.  
 
Molecular cloning 
 Genes of interest were PCR-amplified as detailed above. PCR products were purified 
using the QIAquick PCR purification kit (Qiagen 28104) according to the manufacturer’s 
protocol, followed by digestion with the indicated restriction enzymes (RE, Table 2). Plasmids of 
interest were digested concurrently using RE listed in Table 2. Briefly, 200ng PCR products or 
1μg isolated plasmid were combined with restriction digest buffer and RE for final 
concentrations of 1x CutSmart buffer (NEB B7204S) and 10 units of each appropriate RE (Table 
2). Nuclease free water was used to achieve a final volume of 20μL where necessary, and the 
digestion carried out at 37°C for 2 hours. After digestion, 1μL of calf intestinal phosphatase (CIP, 
NEB M0508S) per 3kb DNA was added to each reaction in order to prevent DNA ends from 
ligating to each other. Reactions were incubated at 37°C for an additional 10 minutes, followed 
by deactivation of CIP at 80°C for 2 minutes and holding at 4°C. Digestion was confirmed by 
agarose gel electrophoresis as described above and the desired plasmid fragments were excised 
and purified using the QIAquick gel extraction kit (Qiagen 28704) according to the 
manufacturer’s protocol. Digested PCR products were also purified using the QIAquick PCR 
purification kit. Digested plasmid and PCR products were combined in a 1:3 molar ratio 
(plasmid:gene) with addition of T4 DNA ligase (NEB M0202S) and ligation buffer (NEB B0202S) at 
final concentrations of 5% T4 DNA ligase and 1x buffer. Nuclease-free water was added to bring 





Transformation by heat shock 
Ligation products were transformed into MAX efficiency DH5α competent E. coli cells 
(Invitrogen 18258012) using the heat shock method according to the manufacturer’s protocol. 
Briefly, 1μL of ligation products was added to 50μL of competent cells and incubated at room 
temperature for 1 hour. The mixture was heat-shocked for 90 seconds at 42°C using a 
BioExpress GeneMate digital dry bath heat block to permeabilize bacteria and subsequently 
cooled on ice for 2 minutes. Super optimal broth with catabolite repression (SOC broth, NEB 
B9020S) was added to cells in a 1:10 ratio (cells:broth) and incubated with shaking for 1 hour at 
37°C to allow expression of antibiotic resistance genes. The entire volume of each culture was 
plated on separate LB agar plates containing antibiotics according to the resistance cassette 
present in the transformed plasmid and plates were incubated at 37°C for 16 hours. Resulting 
colonies were selected for regrowth in antibiotic-containing LB broth and screened for the 
inserted gene of interest by a modified form of colony PCR, as described below. Individual 
colonies positive by PCR were subcultured in 11mL of LB broth containing appropriate 
antibiotics and incubated at 37°C for 20 hours. Culture stocks containing 50% glycerol were 
stored at -80°C. Plasmid was isolated from the remaining culture, as described above, in order to 




 In preparation for site-directed mutagenesis (SDM) of relMtb, the gene was PCR-amplified 
from the H37RvSA laboratory strain of M. tuberculosis [28] using relMtb primer sequences listed 
in Avarbock et al [32] (Table 1) and cloned into a pET15b plasmid vector, as detailed above. SDM 
was performed using the QuikChange Lightning Site-Directed Mutagenesis kit (Agilent 
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Technologies 210518) with minor changes to the manufacturer’s protocol. Briefly, 
complementary mutagenic PCR primers were designed to include a single nucleotide difference 
yielding an amino acid change from aspartic acid to alanine at codon 81 of the relMtb gene (Table 
1). The mutant plasmid was synthesized by PCR using these primers and the non-mutated 
parental plasmid DNA was digested using a DpnI RE to improve transformation efficiency of the 
mutated plasmid. Due to both the cells provided in the QuikChange Lightning SDM kit and the 
pET15b plasmid containing an ampicillin resistance cassette, alternative cells were required to 
screen for plasmid-containing cells by antibiotic resistance. Therefore, 2μL of mutated plasmid 
was transformed into MAX efficiency DH5α competent E. coli cells using the heat shock method, 
as described above. Individual colonies were screened for relMtb by colony PCR and stocks were 
made, as detailed above. Plasmid DNA was isolated from PCR-positive cultures and the correct 
point mutation confirmed by Sanger sequencing, as described below. This plasmid was 
designated pET15b/RelMtbD81A 
 
RelMtbD81A and GFP control plasmid construction 
 gfp and relMtbD81A were PCR-amplified from pUV15tetORm and pET15b/RelMtbD81A 
(Table 1), respectively, and cloned into both the pUV15tetORm_F plasmid and the 
pUV15tetORm_R plasmid (Table 2), as described above. Newly ligated plasmids were 
transformed into E. coli by the heat-shock method and colonies were selected on LB plates 
containing 200μg/mL hygromycin, as detailed above. Gene insertion was confirmed by colony 
PCR and Sanger sequencing, as described below, to yield three plasmids: pUV15tetORm_FGFP, 





Colony PCR for preliminary confirmation of gene insertion 
 The modified form of colony PCR described here was used to screen transformants for 
the gene of interest before sending samples for definitive confirmation by Sanger sequencing, 
detailed in a separate section below. Genes of interest were PCR-amplified from culture with 
Taq DNA Polymerase (NEB M0267S) according to the manufacturer’s protocol. Briefly, 
components were mixed to achieve the following final concentrations: 1.25U Taq DNA 
Polymerase, 1x ThermoPol reaction buffer, 200μM dNTPs (Thermo Scientific R0192), 0.2μM 
forward and reverse primers (Table 1), 1μL culture, and nuclease-free water to a total volume of 
25μL. Reactions were performed on a Bio-Rad MyCycler thermal cycler at an initial denaturation 
temperature of 95°C for 30 seconds followed by thirty-five cycles of denaturation at 95°C for 30 
seconds, primer-specific annealing at temperatures listed in Table 1 for 1 minute, and extension 
at 68°C for 1 minute/kb (2 minutes for relMtb and 1 minute for gfp). A final extension was 
performed at 68°C for 5 minutes and reactions were then held at 4°C until confirmation of PCR 
amplification by agarose gel electrophoresis, as described above. 
 
Sanger sequencing 
 This section details sample preparation for Sanger sequencing completed by Eurofins 
Genomics LLC, and confirmation of sequence similarity to the appropriate publicly available DNA 
sequence by BLAST analysis. The plasmid of interest was combined with a single desired primer 
(Table 3) for final concentrations of 66.7ng/μL plasmid and 0.2μM primer in a 12μL volume. 
Samples were labeled and sent to Eurofins Genomics for Sanger sequencing in accordance with 
the company’s protocols. BLAST analysis was performed by aligning plasmid sequencing reads 
with appropriate known DNA sequences. Reads having ≥90% similarity to their respective known 
sequence were considered confirmed as matching the DNA sequence in question. 
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Transformation by electroporation 
 The pUV15tetORm_FGFP, pUV15tetORm_RGFP, and pUV15tetORm_FRelMtbD81A 
plasmids were isolated from E. coli cultures and transformed into wild type M. smegmatis by 
electroporation as described by Larsen [60]. Briefly, M. smegmatis was grown to mid-log phase 
(OD 0.5), incubated for 10 minutes on ice, pelleted by centrifugation, and washed with one 
volume of ice-cold 10% glycerol three times before final resuspension in 10% glycerol at 1/10th 
the original culture volume. 400μL of M. smegmatis culture and 2μL of plasmid were mixed on 
ice in a pre-chilled Gene Pulser cuvette with a 0.2cm electrode gap (BioRad 165-2082) and 
electroporated using a Bio-Rad GenePulser II set at 2.5kV, resistance 1,000Ω, and capacitance 
25µF. 2mL of media was added immediately after transformation and cultures were incubated 
with shaking for 2 hours at 37°C to allow expression of antibiotic resistance genes, followed by 
plating 50µL of culture on 7H10 agar containing 50μg/mL hygromycin. Plates were incubated at 
37°C and colonies selected after four days of growth. Integration of the respective gene of 
interest was confirmed by PCR amplification, as described above, after DNA isolation, as 
detailed below, as well as Sanger sequencing. 
 
DNA isolation 
 M. smegmatis genomic DNA was isolated either by scraping a single colony from agar or 
pelleting 10mL of culture, resuspending in 600μL of media, and transferring to a 2mL lysing 
matrix B tube containing 0.1mm silica beads (MP Biomedicals 6911-050). Regardless of the 
source, an equal volume of phenol solution (Sigma P4557-400ML) was added and bacteria 
vortexed for 1 minute at maximum speed. Samples were then centrifuged for 2 minutes at 
16,000g, the top layer transferred to one volume of chloroform/isoamyl (24:1)[choloform 
(Fisher Scientific C289-500):isoamyl (J.T.Baker 9038-01)], vortexed briefly, and centrifuged for 2 
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minutes at 16,000g. The aqueous layer was transferred to 1/10th volume of 3M sodium acetate 
(Fisher Scientific 5210-500) with subsequent addition of two volumes of 100% EtOH. Samples 
were pelleted by centrifugation for 15 minutes at 16,000g, followed by two washes with 70% 
ethanol and air-dried for 15 minutes. DNA was resuspended in 100μL Tris-EDTA (TE) buffer, the 
concentration determined by measurement using a NanoDrop 2000 spectrophotometer, and 
stored at -20°C. 
 
RNA isolation and qRT-PCR 
 In preparation for RNA isolation a 10mL culture of M. smegmatis was pelleted, 
resuspended in 1mL of TRIzol (Ambion 15596018), and subjected to bead beating in 2mL lysing 
matrix B tubes containing 0.1mm silica beads (MP Biomedicals 6911-050) using a Bead Bug 
Microtube Homogenizer at speed 400x10 for 1 minute. 200µL of chloroform was added to each 
sample and centrifuged for 10 minutes at 20,000g and 4°C. The aqueous phase was removed 
into an equal volume of 70% ethanol and RNA was isolated following the manufacturer’s 
protocol for the RNeasy mini kit (Qiagen 74104). RNA was eluted in 30µL of EB buffer and 
concentrations were determined by Nanodrop measurement and stored at -20°C. cDNA was 
synthesized from isolated RNA using the QuantiTect reverse transcription kit (Qiagen 205314) 
and following the manufacture’s protocol with the exception of adding RNase free water for a 
final volume of 70µL and a final concentration of 0.63ng/µL cDNA. qPCR was performed utilizing 
the QuantiTect SYBR Green PCR kit (Qiagen 204143) and halving the volumes used in the 
manufacturer’s protocol. Analysis was performed using the 2-ΔΔCT method. qPCR primers for 





Protein collection and western blotting 
 M. smegmatis protein was collected by pelleting 10mL of culture and resuspending in 
300µL of protein buffer consisting of the following components at final concentrations of 1x 
RIPA buffer (Cell Signaling 9806S), 1x phosphatase inhibitor (Thermo Scientific 78428), and 1x 
protease inhibitor (Thermo Scientific 78430). Samples were subjected to bead beating as 
described for RNA isolation and qRT-PCR and supernatant transferred to new microcentrifuge 
tubes. A colorimetric BCA protein assay (Pierce 23227) was performed to quantify the amount of 
total protein in each sample and determine the volume of protein utilized for western blotting. 
20µg of total protein was run on a 4%-15% Mini PROTEAN TGX gel (BioRad 456-1086) using a 
SeeBlue Plus2 prestained standard (Invitrogen LC5925) as a known standard to compare and 
identify approximate sizes of protein bands. Gels were run at 150V for 1 hour and transferred to 
a nitrocellulose membrane (BioRad 162-0097) using a BioRad Trans-Blot SD Semi-Dry transfer 
cell set at 20V for 25 minutes. The membrane was washed in TBST (1x TBS (BioRad 1706435) 
and 0.1% Tween 20 (Sigma P1379-100ML)) for 5 minutes at room temperature and all 
subsequent washes conducted in the same manner. The membrane was then incubated in 
blocking buffer (5% nonfat dry milk (BioRad 170-6404), 1xTBS, 0.05% Tween 20) for 1 hour, 
washed three times, and incubated covered overnight at 4°C with a RelMtb primary antibody 
from mouse serum. The membrane was then washed three times and incubated for 45 minutes 
with an HRP secondary antibody (Thermo Fisher A16166). Following four washes the membrane 
was exposed to a chemiluminescent substrate (Pierce 32109) and protein bands viewed by 
chemiluminescence, exposing the membrane to film (Thermo Scientific 34090) for 5 minutes 
immediately after introducing the chemiluminescent substrate and developing on a AFP Mini-




Anhydrotetracycline induction time course 
 Large volumes of pUV15tetORm_FGFP and pUV15tetORm_FRelMtbD81A culture were 
grown to an OD of 0.1, whereupon anhydrotetracycline (aTC, 100ng/mL [61]) was added and 
this day designated as day 0. Samples were collected for RNA isolation with time points every 
four hours during the first twenty-four hour period and additional time points at 36 hours, 44 
hours, 48 hours, and 72 hours. RNA was isolated and qRT-PCR performed, as stated above, to 
assess expression levels of the gene of interest at specified time points during growth. 
 
Growth kinetics assay 
 Large volumes of pUV15tetORm_FGFP and pUV15tetORm_FRelMtbD81A culture were 
grown to an OD of 0.1, whereupon anhydrotetracycline (aTC, 100ng/mL) was added and this day 
designated as day 0. OD was measured every four hours for the first twenty-four hour period 
with additional measurements at 36 hours, 44 hours, 48 hours, and 72 hours. OD values were 
graphed with respect to time to assess growth kinetics of each bacterial strain. 
 
Results 
Isolation of relMtb and relMtbH80A 
 A balance between the (p)ppGpp synthesis and hydrolysis activities of RelMtb is required 
for normal homeostatic functioning of M. tuberculosis (Figure 5A). Avarbock et al [48] has shown 
that specific point mutations eliminate the (p)ppGpp hydrolysis function of RelMtb while 
preserving the synthesis function of the enzyme. We hypothesize that overexpression of a 
hydrolysis-deficient version of RelMtb in M. tuberculosis would phenocopy induction of the 
stringent response, in which (p)ppGpp accumulates (Figure 5C).  
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A pET15b plasmid containing the wild type relMtb gene from M. tuberculosis clinical 
strain CSU11/22 and a pET22b plasmid containing relMtb from the same background with a 
hydrolysis ablating point mutation at amino acid 80 (relMtbH80A; both kind gifts of Dr. Harvey 
Rubin, University of Pennsylvania) were individually transformed into E. coli. Although liquid 
cultures of E. coli containing the pET15b/RelMtb plasmid achieved turbidity within 4 hours, those 
containing the pET22b/RelMtbH80A plasmid did not become turbid until after three days. In 
order to confirm the presence of the desired plasmids, a diagnostic digest was performed on the 
pET15b/RelMtb and pET22b/RelMtbH80A plasmids using the respective enzymes listed in Table 2 
and visualized by agarose gel electrophoresis. Expected DNA bands at sizes of 2214bp and 
5406bp were visible for digested pET15b/RelMtb (Figure 7), preliminarily confirming the presence 
of this plasmid and the gene of interest it contained. However, DNA bands were absent for 
Figure 7 Diagnostic digest of pET15b/RelMtb and pET22b/RelMtbH80A Diagnostic digest of pET15b plasmids containing 
wild type RelMtb (pET15b/RelMtb WT, lanes 3 and 4) or hydrolysis-deficient RelMtb (pET15b/RelMtbH80A, lanes 5-7) 
conferred by a point mutation at position 80. The table indicates expected sizes of bands based on plasmid size and 
restriction enzymes utilized. 
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digested pET22b/RelMtbH80A (Figure 7) despite quantification of nucleic acids by Nanodrop. As 
an alternative approach, larger volumes of pET22b/RelMtbH80A culture were grown to obtain 
high enough plasmid concentrations for sequencing. With an adequate amount of plasmid 
available, samples were prepared and sent for sequencing of relMtb from both pET15b/RelMtb and 
pET22b/RelMtbH80A plasmids using the primers listed in Table 3. Resulting reads were compared 
to the genetic sequence of relMtb obtained from Tuberculist [62] using BLAST analysis, and 
successfully confirmed the pET15b/RelMtb plasmid did indeed contain actual relMtb. However, 
upon comparison of reads from pET22b/RelMtbH80A with the genetic sequence of relMtb from 
Tuberculist in the same manner, no significant matches were observed. In a final effort to 
enhance production and confirm the presence of the pET22b/RelMtbH80A plasmid, isolated 
plasmid was transformed into a new strain of DH5α E. coli by the heat shock method. No 
detectable transformants were visualized on LB/ampicillin plates despite successful 
transformation of a pUC19 control. Negative results obtained by diagnostic digest, Sanger 
sequencing, and transformation determined that further work with this sample would be 
abandoned in favor of synthesis of a new hydrolysis-deficient relMtb from M. tuberculosis 
genomic DNA. 
 
Synthesis of hydrolysis-deficient RelMtbD81A 
 Although the pET15b/RelMtb plasmid contained wild type relMtb, the source of this gene 
was a clinical M. tuberculosis isolate. To ensure consistency with previously published studies 
and the majority of TB literature, relMtb was PCR-amplified from the well-characterized M. 
tuberculosis laboratory reference strain H37RvSA using the primers listed in Table 1, cloned into 
pET15b with the RE listed in Table 2, and the insertion was confirmed by Sanger sequencing 
using the primers listed in Table 3 followed by BLAST analysis against the Tuberculist relMtb 
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genetic sequence. Mutation of amino acids at codon 80 or 81 abolishes RelMtb hydrolysis activity 
[48]. However, codon 81 requires only a single nucleotide change, whereas codon 80 requires 
two nucleotide changes. Therefore, a point mutation introduced by site-directed mutagenesis 
and yielding an amino acid change from aspartic acid to alanine at codon 81 of the relMtb gene 
was chosen to eliminate its hydrolysis function. This single nucleotide change was confirmed by 
Sanger sequencing using the primers listed in Table 3 followed by BLAST analysis against the 




Figure 8 Confirmation of relMtbD81A site-directed mutagenesis by Sanger sequencing Results of BLAST analysis 
querying the wild type relMtb gene sequence against Sanger sequencing results of putative relMtbD81A. The single 




Confirmation of pUV15tetORm plasmid backbones and gene insertion 
 Overexpression of hydrolysis-deficient RelMtbD81A is predicted to be sufficient to induce 
the stringent response through dysregulated accumulation of (p)ppGpp, resulting in slowed 
bacterial replication, even in nutrient rich conditions. However, we considered the possibility 
that excessively elevated (p)ppGpp levels due to constitutive overexpression of RelMtbD81A may 
be lethal. Therefore, we pursued a strategy of conditional overexpression of RelMtbD81A using a 
tetracycline-inducible system. A tetracycline controlled transactivator (tTA), created by fusion of 
a tetracycline repressor (tetR) and a virion protein from herpes simplex virus, binds to a repeat 
sequence of tetracycline operators (tetO) known as the tetracycline response element (TRE). 
This TRE is positioned upstream of a minimal promoter and binding of the tTA triggers 
expression of the gene of interest. In this tetracycline off (tetoff) system introduction of 
tetracycline reduces gene expression dramatically by binding to and removing tTA from the TRE 
[63]. However, reducing gene expression after addition of tetracycline in the tetoff system 
requires more than two days, posing the risk of stringent response induction at the initial phase 
of growth in the current study. In contrast, the tetracycline on (teton) system [64] possesses a 
mutated tTA that only binds to the TRE in the presence of tetracycline. Utilizing this system 
provides the opportunity for bacterial growth to log phase before inducing expression of 
RelMtbD81A. 
Another consideration was the ability to stably integrate the gene of interest into a 
mycobacterial genome. Inclusion of the attP attachment site and integrase originally found in 
the L5 mycobacteriophage has been shown to allow integration of plasmids that contain these 
elements into M. smegmatis, bacille Calmette-Guerin (BCG), and M. tuberculosis genomes [65]. 
Both the attP site in the plasmid and an attB attachment site in the bacterial genome possess a 
homologous core region that allows for site-specific recombination with assistance from the 
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integrase. The result is stable insertion of the plasmid sequence, including the gene of interest, 
into the bacterial genome at the attB site. Incorporating the gene of interest into the 
mycobacterial genome eliminates the need for continual antibiotic selection. It also provides the 
added advantage of enabling further study of any observed in vitro phenotypes in animal 
models due to stable maintenance of the gene of interest within the mycobacterial genome and 
the ability to use the well tolerated tetracycline analog doxycycline to induce expression of the 
gene of interest. 
The teton plasmid pUV15tetORm containing a mycobacterial specific promoter, a gift 
from Sabine Ehrt (Addgene plasmid #17975) [66], was modified by previous lab member Dr. Yu-
Min Chuang to include an attP attachment site and an integrase [56]. This plasmid backbone 
was designated as pUV15tetORm_F (Figure 9). In vivo experiments previously performed with a 
strain of M. tuberculosis containing the pUV15tetORm_F plasmid backbone integrated into its 
genome showed both the empty vector control lacking an inserted gene of interest and the test 
plasmid containing the gene of interest displayed a similar altered phenotype when compared 
to wild type M. tuberculosis. In order to determine whether the observed phenotype was an 
original phenomenon of the gene of interest or merely an effect of the plasmid backbone, the 
TRE and promoter were repositioned in the plasmid backbone to allow positioning of the gene 
of interest in a reverse orientation compared to the pUV15tetORm_F plasmid. This plasmid 
possessing the gene of interest in a reverse orientation was designated pUV15tetORm_R (Figure 
9) and it was determined that the corresponding empty vector control did not display the 
altered phenotype seen previously. The observed phenotype was, therefore, attributed to the 
gene of interest and not a general effect of the plasmid backbone. 
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Upon receipt of the pUV15tetORm_F and pUV15tetORm_R plasmids for the current 
study their identity was confirmed by diagnostic digest. This diagnostic digest was performed on 
the pUV15tetORm_F and pUV15tetORm_R plasmids using the respective enzymes listed in Table 
2 and visualized by agarose gel electrophoresis. Two DNA bands at the expected sizes of 1000bp 
and 5968bp for digestion with AclI and PacI RE or 387bp and 6552bp for digestion with SpeI and 
PacI RE were visible after digestion of pUV15tetORm_F (Figure 10), preliminarily confirming its 
identity. Three DNA bands at the expected sizes of 351bp, 977bp, and 5602bp for digestion with 
AclI and PacI RE or two DNA bands at the expected sizes of 1000bp and 5926bp for digestion 
Figure 9 pUV15tetORm_F and pUV15tetORm_R plasmid maps Plasmid maps for pUV15tetORm_FGFP (A), 
pUV15tetORm_FRelMtbD81A (B), pUV15tetORm_RGFP (C), and pUV15tetORm_FRelMtbD81A (D) with relevant 
restriction enzymes and features displayed. Origin of replication (yellow), tetracycline operator (teal), gene of interest 




with SpeI and PacI RE were visible after digestion of pUV15tetORm_R (Figure 10), also 
preliminarily confirming its identity. Additionally, Sanger sequencing using the primers listed in 
Table 3 followed by BLAST analysis against genetic sequences provided by Dr. Yu-Min Chuang 
also confirmed the identity of the two plasmid backbones. A majority of both the 
pUV15tetORm_F and pUV15tetORm_R plasmid reads were accounted for in their respective 
provided plasmid sequences. Portions of the known plasmid sequences not present in any of the 
reads were likely due to reads that did not extend long enough to overlap with the subsequent 
staggered read, not necessarily because the plasmids were missing a portion of their expected 
sequence. These portions that were unaccounted for were also either small enough or in 
locations that likely would not significantly impact expression of crucial elements contained in 
Figure 10 Diagnostic digest of pUV15tetORm_F and pUV15tetORm_R plasmids Diagnostic digest of pUV15tetORm_F 
(lanes 1 and 2) and pUV15tetORm_R (lanes 3 and 4) plasmid backbones. The table indicates expected sizes of bands 
based on plasmid size and restriction enzymes utilized. 
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the plasmids. Therefore, we concluded that the pUV15tetORm_F and pUV15tetORm_R plasmids 
were indeed the actual pUV15tetORm_F and pUV15tetORm_R plasmids and may be utilized as 
such. Instead of using an empty vector control, gfp was chosen for insertion into the plasmid 
backbones as a control gene due to the added benefit of easy visual confirmation of expression 
both in vitro and in vivo. In addition, use of this gene as a control in the teton system has been 
previously validated [67]. gfp and relMtbD81A were PCR-amplified from the pUV15tetORm and 
pET15b/RelMtbD81A plasmids, respectively, using the primers listed in Table 1 and inserted 
separately into the pUV15tetORm_F and pUV15tetORm_R plasmid backbones by molecular 
cloning. Insertion of these genes was confirmed by a modified form of colony PCR using the 
same primers referenced above and visualization of DNA bands between 500kb and 750k or 
2000kb and 2500kb for gfp and relMtb, respectively (Figure 11). Gene insertion was also 
confirmed by Sanger sequencing using the primers listed in Table 3 followed by BLAST analysis 
against the gfp genetic sequence from the pUV15tetORm plasmid, a gift from Sabine Ehrt 
(Addgene plasmid #17975) [66], and the Tuberculist relMtb genetic sequence [62]. These 
plasmids with their respective gene insertions were designated pUV15tetORm_FGFP, 
pUV15tetORm_RGFP, and pUV15tetORm_FRelMtbD81A. 
 
Electroporation of plasmids into Mycobacterium smegmatis 
 M. smegmatis is a nonpathogenic, rapidly growing species of Mycobacteria frequently 
used as a surrogate for M. tuberculosis. It produces a bifunctional Rel protein capable of 
synthesizing and hydrolyzing (p)ppGpp [54] and required for survival in stressed conditions [68]. 
Because of these similarities between M. tuberculosis and M. smegmatis, phenotypes observed 
in the two bacteria often mirror each other. Taking advantage of these qualities, initial 
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experiments were performed in M. smegmatis as proof of concept for pursuing further studies 
in M tuberculosis. pUV15tetORm_FGFP, pUV15tetORm_RGFP, and pUV15tetORm_FRelMtbD81A 
plasmids were transformed into M. smegmatis by electroporation and plated on 7H10 plates 
containing hygromycin (50µg/mL). Single colony isolates were selected after incubation for four 
days at 37°C and their respective gene integrations confirmed by colony PCR (Figure 12) and 
Figure 12 Confirmation of gfp and relMtbD81A 
insertion into plasmid backbones by PCR Agarose 
gel electrophoresis of PCR products from 
pUV15tetORm_FGFP (gfp, lane 3), 
pUV15tetORm_RGFP (gfp, lane 4), and 
pUV15tetORm_FRelMtbD81A (relMtb, lane 5) and 
confirmation of the gene insertion of interest by 
visualization of the appropriate size DNA band. 
Figure 11 Confirmation of gfp and relMtbD81A 
integration into the M. smegmatis genome by PCR 
Agarose gel electrophoresis of PCR products from M. 
smegmatis_FGFP (gfp, lane 3), M. smegmatis_RGFP 
(gfp, lane 4), and M. smegmatis_FRelMtbD81A (relMtb, 
lane 5) and confirmation of the gene insertion of 




Sanger sequencing using the primers listed in Tables 1 and 3, respectively. The resulting strains 
were designated M. smegmatis_FGFP, M. smegmatis_RGFP, and M. smegmatis_FRelMtbD81A.  
 
qPCR 
In order to confirm induced genetic expression of the genes of interest, a time course 
was conducted and gene expression measured by qPCR at various time points over three days. 
Expression of relMtb in M. smegmatis_FRelMtbD81A increased gradually to a maximum of just 
over ten-fold 48 hours after induction with the anhydrotetracycline inducer (Figure 13A). 
Negative controls remained at very low levels or were undetermined. 
 
Western blot 
In order to confirm expression at the protein level, a time course was conducted and 
protein expression measured by western blot at various time points over three days. 
Confirmation of the specificity of the RelMtb antibody was of particular importance considering 
the presence of RelMsm in the strains utilized for this experiment. Therefore, the 24 hour, 48 
hour, and 72 hour time points for both M. smegmatis_FGFP and M. smegmatis_FRelMtbD81A 
were probed with RelMtb antibody, revealing a protein band at approximately 75kd in M. 
smegmatis_FGFP samples. Though the presence of this 75kd protein band in M. 
smegmatis_FGFP samples indicated nonspecific binding of the antibody, an additional protein 
band in the M. smegmatis_FRelMtbD81A samples at the expected weight of approximately 82kd 
restored confidence in the utility of the antibody to accurately distinguish RelMtb (Figure 13B). 
Upon additional probing with the RelMtb antibody, expression of RelMtb in M. 
smegmatis_FRelMtbD81A was found to gradually increase up to 72 hours after introduction of 
the inducer (Figure 13C). Samples from time points preceding 12 hours did not contain enough 
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 To assess differences in growth rate between M. smegmatis_FGFP and M. smegmatis_ 
FRelMtbD81A a growth curve was generated from OD measurements collected during the time 
course previously mentioned (Figure 14). This growth curve did not illuminate differences in 
growth kinetics between the two strains in question. 
Figure 13 Anhydrotetracycline induction of gene and protein expression Confirmation of inducible expression over 
time by RT-PCR (A) and immunoblot (B, C) A) relMtb gene expression at select time points after induction with 
anhydrotetracycline in a 72 hour time course. B) Confirmation of antibody specificity for RelMtb by probing M. 
smegmatis_FRelMtbD81A (lanes 1-3) and M. smegmatis_FGFP (lanes 4-6) protein samples with RelMtb antibody at 
select time points in a 72 hour time course. C) RelMtb protein expression after induction with anhydrotetracycline in a 





Mycobacterium tuberculosis is a pathogenic microorganism causing tuberculosis, a 
disease that has prevailed as one of the top killers worldwide and was responsible for almost 
two million deaths in 2016 [4]. The extended six-month duration of treatment for antibiotic 
sensitive TB complicates effective completion of treatment regimens and is thought to be the 
result of a small population of nonreplicating, persistent bacteria. Strategies to disrupt this 
population of bacteria are needed in order to more efficiently kill M. tuberculosis and shorten 
the duration of treatment, hopefully aiding in the eventual elimination of TB. 
Persistent M. tuberculosis employs the stringent response pathway as a method of 
reducing replication and metabolic activity to withstand killing by antibiotics without the 
necessity of possessing a genetic mutation causing antibiotic resistance. The effector molecule 
of this pathway is (p)ppGpp, whose maintenance within the bacterial cell is controlled by the 
bifunctional enzyme RelMtb. There is optimism that learning how to control RelMtb function may 
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Figure 14 Growth kinetics Growth kinetics of M. smegmatis_FGFP and M. smegmatis_FRelMtbD81A after induction 
with anhydrotetracycline in a 72 hour time course 
41 
 
enable modulation of the stringent response. With the capacity to influence whether or not M. 
tuberculosis transitions to a persistent state arises the opportunity to drive the bacteria into a 
more uniform population of replicating microorganisms. This continuity could give current first-
line antibiotics affecting replicating bacteria, such as isoniazid, the power to more efficiently 
target a homogeneous population of bacteria they are more equipped to confront as opposed 
to struggling against a heterogenous population containing bacteria they are not optimized to 
kill. 
Rel knockout strains have been characterized and much knowledge acquired about its 
role in bacterial growth and the stringent response. A complementary approach to gain 
additional insight into the mechanism of this enzyme and its utility in driving advantageous 
phenotypic changes is creation of a RelMtb knock-in strain capable of inducing the stringent 
response and increasing (p)ppGpp levels in the absence of nutrient deprivation. Generation of 
this overexpression strain has been accomplished by introducing a point mutation into the 
RelMtb gene at a location known to disrupt (p)ppGpp hydrolysis function and placing the gene 
under control of an inducible promoter. In this manner, temporal RelMtbD81A expression can be 
controlled and (p)ppGpp synthesis function remains intact to allow accumulation of this 
alarmone and induction of the stringent response. A relMtbD81A gene in the forward orientation 
with respect to the genome and its corresponding GFP control gene have been integrated into 
separate M. smegmatis genomes and inducible expression of RelMtb confirmed at the genetic 
and protein level. This strain is currently available for further functional characterization. 
A growth curve measuring bacterial growth kinetics in the M. smegmatis_FRelMtbD81A 
strain revealed no difference in growth rate between this strain and its respective control strain. 
This finding was initially unexpected because rising (p)ppGpp levels and induction of the 
stringent response would anticipate an early plateau and entrance into stationary phase before 
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the control strain. However, this growth curve was constructed based on optical density 
measurements, which do not always reflect changes in viability and can be deceiving due to 
effects from stress induced changes in the bacterial cell wall on distortion of light refraction. In 
addition, previous observation of an undesirable in vivo phenotype for the control 
pUV15tetORm_F backbone utilized to create the forward orientation M. smegmatis_FGFP strain 
was the rationale for generating a second, reverse orientation strain. The in vivo findings of this 
forward orientation backbone may explain the seeming lack of a phenotype in vitro. It is feasible 
that both the M. smegmatis_FGFP and M. smegmatis_FRelMtbD81A strains display a phenotype 
that is unrecognizable without inclusion of the parental M. smegmatis strain excluding 
integration of the pUV15tetORm_F plasmid. Conversely, other groups have reported the lack of 
an effect on viability in a RelMsm knockout strain of M. smegmatis [69], but reduced survival in a 
competition assay against the wild type strain [68], with both groups reporting data using a 
more accurate measure of CFU counts. In light of these conflicting positions, future functional 
characterization of the forward orientation strain should include the parent M. smegmatis strain 
and a growth curve based on more reliable CFU counts should be constructed to address the 
issues presented by questionable viability and effects of cell wall distortion inherent in 
utilization of the optical density technique. Another possible reason for a lack of difference in 
growth rate is the presence of native RelMsm. There is no reason to believe RelMsm would 
discriminate against (p)ppGpp made by RelMtbD81A. It is conceivable that while RelMtbD81A 
should make increasing amounts of (p)ppGpp without hydrolyzing it, this product is being 
hydrolyzed by fully functional RelMsm as quickly as it is synthesized, resulting in a net effect of 
zero. 
In addition to confirming inducible expression of RelMtb in the reverse orientation strain, 
further functional characterization of both the forward and reverse orientation RelMtbD81A 
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strains is warranted. Measurement of (p)ppGpp levels using high-performance liquid 
chromatography (HPLC) or P32 radioactive labeled nucleotides and thin layer chromatography 
would be informative in understanding the effects of eliminating RelMtb hydrolysis function and 
confirm that RelMtb overexpression is sufficient to induce the stringent response. Alternatively, 
poly(P) levels typically rise with increasing (p)ppGpp levels and can be utilized as a simpler, 
though indirect, measure of (p)ppGpp synthesis. With the increased presence of (p)ppGpp and 
induction of the stringent response, a diminished growth rate and premature entrance into 
stationary phase in the RelMtbD81A strain before its GFP control counterpart is hypothesized. 
However, another question concerning the effect of (p)ppGpp overexpression relates to 
bacterial viability under an excessive stringent response. To address whether or not bacteria 
enter a dormant state or die due to toxic levels of (p)ppGpp exposure, performing a bacterial 
viability assay would aid in gaining valuable knowledge regarding the difference between live 
and dead populations of bacteria during growth. A replication clock assay [70] in which 
retention of a replication clock plasmid is measured over the course of twenty-one days may 
also assist in elucidating useful information about bacterial growth rates. This assay makes use 
of natural plasmid loss in the absence of antibiotic pressure and plating on agar plates with and 
without antibiotics to reveal the portion of bacteria that retain the replication clock plasmid and 
enables calculation of the rate at which bacteria replicate. As high retention of plasmid indicates 
a slower replication rate, and low plasmid retention signifies a faster replication rate, one would 
expect the RelMtbD81A strains to retain more plasmid than the controls due to increased 
(p)ppGpp, induction of the stringent response, and inhibition of replication. Importantly, the 
effects of (p)ppGpp accumulation on antibiotic efficacy should be tested. When bacteria are 
exposed to increasing concentrations of antibiotic in a minimum bactericidal concentration 
(MBC) assay, the concentration of antibiotic necessary to cause a 2 log10 CFU (99%) reduction of 
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bacteria is considered the MBC of the antibiotic. Of particular interest is the efficiency of the 
first-line therapeutic isoniazid in killing the RelMtbD81A strains. Because RelMtbD81A strains are 
predicted to increase (p)ppGpp levels and induce the stringent response in nutrient rich 
conditions, they are expected to display phenotypic tolerance to isoniazid. Thus, the MBC of 
isoniazid should be higher than that required for wild type M. smegmatis in nutrient rich 
conditions. Furthermore, the plasmid constructs generated in this study may also be utilized to 
extend exploration of growth and antibiotic tolerance phenotypes to M. tuberculosis. In these 
studies, it would be advantageous to exploit the availability of the ΔrelMtb strain of M. 
tuberculosis, as this would eliminate effects potentially caused by background RelMtb expression. 
Use of small molecule inhibitors of RelMtb may also be beneficial in modulating the 
stringent response to phenocopy ΔrelMtb strains. The potential of these small molecules to elicit 
beneficial phenotypes is an exciting advancement, as they may be optimized and manufactured 
as medications. With RelMtb as a prospective druggable target, innovative ways of shortening TB 
treatment regimens by targeting the persistent population of nonreplicating bacteria may be 
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Table 1 Primers for PCR amplification, site-directed mutagenesis, and qPCR 
 
Primer Name Sequence Purpose Annealing Temperature 






ACCACCAAT - 3' 
 
Amplification of 





























G - 3' 






ATGGCTAGCCAAGGAGAAG - 3' 
Amplification of 










TTATTTGTAGAGCTCATCCATG - 3' 






ATGGCTAGCCAAGGAGAAG - 3' 
Amplification of 










TTATTTGTAGAGCTCATCCATG - 3' 



















CACCCGGTA - 3' 
 
































5' - AGCTTGTTGATCACCTCGAC - 3' 
 
gfp qPCR Forward 
primer 
























Table 2 Restriction enzymes for gene insertions and diagnostic digests 
 
Restriction Enzyme Sequence Purpose 
Pac1 5' - TTAATTAA - 3' Gene insertion, diagnostic 
digest 
Acl1 5' - AACGTT - 3' Gene insertion, diagnostic 
digest 
Spe1 5' - ACTAGT - 3' Gene insertion, diagnostic 
digest 
Nde1 5' - CATATG - 3' Gene insertion, diagnostic 
digest 
BamH1 5' - GGATCC - 3' Gene insertion, diagnostic 
digest 






Table 3 Sequencing primers 
 
Primer Name Sequence Purpose 
relMtb F2 5' - CGGGAGATCTATCCCAAGG - 3' 
 
Confirm complete insertion of 
relMtb; confirm hydrolysis-
eliminating point mutation 
relMtb F6 5' - GTGCATTCGCTATGGCAG - 3' 
 
Confirm complete insertion of 
relMtb 
relMtb F8 5' - GGTTTTCACGTCCAAGGC - 3' 
 




relMtb F10 5' - AAGCTGGCCAAGTGCT - 3' 
 
Confirm complete insertion of 
relMtb 
relMtb R1 5' - AGGTCGGCCTTGGGATAG - 3' 
 
Confirm complete insertion of 
relMtb 
gfp F1 
5' - AAACGGCCACAAGTTCAG - 3' 
Confirm complete insertion of 
gfp 
gfp F2 
5' - ACTTCTTCAAGTCCGCCA - 3' 
Confirm complete insertion of 
gfp 
gfp F3 
5' - GAGTACAACTACAACAGCCA - 3' 
Confirm complete insertion of 
gfp 
gfp F4 
5' - AACGAGAAGCGCGATCACAT - 3' 
Confirm complete insertion of 
gfp 
gfp R1 5' - CTGAACTTGTGGCCGTTT - 3' 
 
Confirm complete insertion of 
gfp 
pUV15tetORm_F F1 
5' - CGGGAGAACTCCCTATCAG - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F2 
5' - GACAGTGTGGTCATCGTTC - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F3 
5' - GTCATCGCAAAGAAAACGTC - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F4 
5' - GCCGGTCAAGATAGGTTTTT - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F5 
5' - GACCTACGACAACAAGATGG - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F6 
5' - TGAGATCTTCGAGCACTACC - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F7 
5' - ATGAAGGACCGTACGAAGAT - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F8 
5' - ATGTAGAGCTGGTCGTTGTA - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F9 
5' - GTTTCGTGTGGTTGCTAGAT - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F10 
5' - AAATATTGGATCGTCGCACC - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F11 
5' - AGGTCGGAATCGAAGGTTTA - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F12 
5' - CAGAGCCAGCCTTCTTATTC - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F13 
5' - CAGGTCCACGAAGATGTTG - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F14 
5' - CCGAACAGCTTGATCACC - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F15 
5' - TGGTAACTGTCAGACCAAGT - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F F16 
5' - GTGAGTTTTCGTTCCACTGA - 3' 





5' - TACAGCGTGAGCTATGAGAA - 3' 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_F R1 5' - CTGATAGGGAGTTCTCCCG - 3' 
 
Confirm genetic sequence of 
pUV15tetORm_F plasmid 
pUV15tetORm_R F1 
5' - GTACCAACTCGATTCGCTT - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F2 
5' - GAACGATGACCACACTGTC - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F3 
5' - GTCGAAATGATGTATGCCGT - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F4 
5' - GCCGGTCAAGATAGGTTTTT - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F5 
5' - GACCTACGACAACAAGATGG - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F6 
5' - TGAGATCTTCGAGCACTACC - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F7 
5' - ATGAAGGACCGTACGAAGAT - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F8 
5' - ATGTAGAGCTGGTCGTTGTA - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F9 
5' - GTTTCGTGTGGTTGCTAGAT - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F10 
5' - AAATATTGGATCGTCGCACC - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F11 
5' - AGGTCGGAATCGAAGGTTTA - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F12 
5' - CAGAGCCAGCCTTCTTATTC - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F13 
5' - CAGGTCCACGAAGATGTTG - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F14 
5' - CCGAACAGCTTGATCACC - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F15 
5' - TGGTAACTGTCAGACCAAGT - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F16 
5' - GTGAGTTTTCGTTCCACTGA - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R F17 
5' - TACAGCGTGAGCTATGAGAA - 3' 
Confirm genetic sequence of 
pUV15tetORm_R plasmid 
pUV15tetORm_R R1 5' - AAGCGAATCGAGTTGGTAC - 3' 
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